Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up - 2Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- 3Iran steps up executions as experts warn state killing being used to suppress political dissent
- 4Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show
- 5Cheetos and Doritos to launch new versions without artificial dyes
- Qatar, Ireland accuse Israel of using chemical weapons on Palestinians, demand watchdog probe use
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- Why home maintenance deserves a spot in the annual health and budget plans
- French lawmakers narrowly approve health care budget, suspending Macron's flagship pension reform
- I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- Instructions to Floss Appropriately and Forestall Gum Sickness
- Dominating Capable Mastercard Utilization: Key Contemplations
- Los Angeles County sees significant uptick in norovirus cases, officials say
